As pharma looks ahead to 2026, greater regulatory and geopolitical clarity is expected to unlock delayed investment decisions, but this is not without new pressures.
In a new article for PharmaVoice, Graham Clark, CEO of Phastar, shares his perspectives on how stabilizing policy and trade conditions may re-energize R&D, while also reshaping the industry’s economic reality.